PL2714926T3 - Biomarkery raka płuca - Google Patents
Biomarkery raka płucaInfo
- Publication number
- PL2714926T3 PL2714926T3 PL12723210T PL12723210T PL2714926T3 PL 2714926 T3 PL2714926 T3 PL 2714926T3 PL 12723210 T PL12723210 T PL 12723210T PL 12723210 T PL12723210 T PL 12723210T PL 2714926 T3 PL2714926 T3 PL 2714926T3
- Authority
- PL
- Poland
- Prior art keywords
- biomarkers
- lung cancer
- lung
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medicinal Preparation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490021P | 2011-05-25 | 2011-05-25 | |
| PCT/EP2012/059784 WO2012160177A1 (en) | 2011-05-25 | 2012-05-24 | Biomarkers for lung cancer |
| EP12723210.6A EP2714926B1 (en) | 2011-05-25 | 2012-05-24 | Biomarkers for lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2714926T3 true PL2714926T3 (pl) | 2015-12-31 |
Family
ID=46148889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12723210T PL2714926T3 (pl) | 2011-05-25 | 2012-05-24 | Biomarkery raka płuca |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140227372A1 (pl) |
| EP (1) | EP2714926B1 (pl) |
| JP (1) | JP2014516531A (pl) |
| KR (1) | KR20140024907A (pl) |
| CN (1) | CN103562409B (pl) |
| AU (1) | AU2012260785B2 (pl) |
| BR (1) | BR112013029787A2 (pl) |
| CA (1) | CA2836844A1 (pl) |
| ES (1) | ES2550192T3 (pl) |
| IL (1) | IL229319A0 (pl) |
| MX (1) | MX340453B (pl) |
| PL (1) | PL2714926T3 (pl) |
| PT (1) | PT2714926E (pl) |
| RU (1) | RU2013157589A (pl) |
| SG (1) | SG194615A1 (pl) |
| WO (1) | WO2012160177A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| BR112017005336A2 (pt) * | 2014-09-17 | 2017-12-12 | Merck Patent Gmbh | método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos |
| WO2016106643A1 (zh) * | 2014-12-31 | 2016-07-07 | 深圳华大基因股份有限公司 | 检测非小细胞肺癌用药相关基因突变的引物及检测方法 |
| CN108369234B (zh) | 2015-10-23 | 2020-12-01 | 豪夫迈·罗氏有限公司 | 基于标志物分子将个体鉴定为待通过化疗治疗的方法和相关用途 |
| CN107022605B (zh) * | 2017-02-27 | 2019-10-15 | 广东医科大学 | 一种活动性肺结核的生物标志物 |
| CN107142320B (zh) * | 2017-06-16 | 2021-03-09 | 上海易毕恩基因科技有限公司 | 用于检测肝癌的基因标志物及其用途 |
| WO2019006156A1 (en) * | 2017-06-29 | 2019-01-03 | Quanticision Diagnostics Inc. | APPARATUS AND METHOD FOR ABSOLUTE QUANTIFICATION OF BIOMARKERS FOR SOLID TUMOR DIAGNOSIS |
| CN109426776A (zh) * | 2017-08-25 | 2019-03-05 | 微软技术许可有限责任公司 | 基于深度神经网络的对象检测 |
| CN109470854B (zh) * | 2017-09-08 | 2022-02-11 | 广州市丹蓝生物科技有限公司 | 肺癌诊断用蛋白芯片及试剂盒 |
| CN109470858B (zh) * | 2017-09-08 | 2022-02-15 | 广州市丹蓝生物科技有限公司 | 肺癌诊断用蛋白芯片及试剂盒 |
| JP2019086348A (ja) * | 2017-11-06 | 2019-06-06 | 公益財団法人ヒューマンサイエンス振興財団 | バイオマーカー及び血液試料中のｖｅｇｆ−ｃ濃度の測定方法 |
| EP3728630A4 (en) * | 2017-12-19 | 2021-11-17 | The Wistar Institute Of Anatomy And Biology | COMPOSITIONS AND METHODS OF DIAGNOSING LUNG CANCER USING GENE EXPRESSION PROFILES |
| US10925875B2 (en) | 2018-01-23 | 2021-02-23 | National Jewish Health | Methods of treating steroid resistant diseases and conditions |
| CN108931587B (zh) * | 2018-04-18 | 2021-09-07 | 湖州市中心医院 | 一种定量筛选nsclc的诊断生物标志物的方法 |
| RU2706116C1 (ru) * | 2018-12-26 | 2019-11-14 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ прогнозирования течения аденокарциномы легкого |
| GB201901439D0 (en) * | 2019-02-01 | 2019-03-27 | Univ London | Method of predicting survival rates for cancer patients |
| CN115023615A (zh) * | 2020-01-10 | 2022-09-06 | 私募蛋白质体操作有限公司 | 确定葡萄糖耐量减低的方法 |
| CN116574805A (zh) * | 2023-02-23 | 2023-08-11 | 上海交通大学医学院 | 一种预测抗pd-1免疫治疗的肺癌预后标记物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589782A1 (en) * | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
| CN101111768A (zh) * | 2004-11-30 | 2008-01-23 | 维里德克斯有限责任公司 | 肺癌预后 |
| EP1980627A1 (en) * | 2007-04-13 | 2008-10-15 | Pangaea Biotech, S.A. | Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression |
| CA2689714A1 (en) * | 2007-06-01 | 2008-12-04 | Agendia B.V. | Prognostic gene expression signature for non small cell lung cancer patients |
| US8211643B2 (en) * | 2008-05-14 | 2012-07-03 | University Health Network | Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy |
| US20110319280A1 (en) * | 2008-07-16 | 2011-12-29 | Oncotherapy Science, Inc. | Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer |
| NO328852B1 (no) * | 2008-09-24 | 2010-05-31 | Moss Maritime As | Fremgangsmate og system for behandling av gass |
| US20120004116A1 (en) * | 2008-12-04 | 2012-01-05 | Ming-Sound Tsao | Methods for biomarker identification and biomarker for non-small cell lung cancer |
| JP4782854B2 (ja) * | 2009-03-10 | 2011-09-28 | ナショナル ヤン−ミン ユニバーシティ | 癌患者の潜在的転移能、予後、又は全生存を予測する方法 |
-
2012
- 2012-05-24 AU AU2012260785A patent/AU2012260785B2/en not_active Ceased
- 2012-05-24 RU RU2013157589/10A patent/RU2013157589A/ru not_active Application Discontinuation
- 2012-05-24 CN CN201280025474.0A patent/CN103562409B/zh not_active Expired - Fee Related
- 2012-05-24 BR BR112013029787A patent/BR112013029787A2/pt not_active IP Right Cessation
- 2012-05-24 KR KR1020137030738A patent/KR20140024907A/ko not_active Withdrawn
- 2012-05-24 EP EP12723210.6A patent/EP2714926B1/en not_active Not-in-force
- 2012-05-24 SG SG2013079074A patent/SG194615A1/en unknown
- 2012-05-24 ES ES12723210.6T patent/ES2550192T3/es active Active
- 2012-05-24 WO PCT/EP2012/059784 patent/WO2012160177A1/en not_active Ceased
- 2012-05-24 JP JP2014511892A patent/JP2014516531A/ja active Pending
- 2012-05-24 PT PT127232106T patent/PT2714926E/pt unknown
- 2012-05-24 US US14/119,604 patent/US20140227372A1/en not_active Abandoned
- 2012-05-24 CA CA2836844A patent/CA2836844A1/en not_active Abandoned
- 2012-05-24 MX MX2013013746A patent/MX340453B/es active IP Right Grant
- 2012-05-24 PL PL12723210T patent/PL2714926T3/pl unknown
-
2013
- 2013-11-07 IL IL229319A patent/IL229319A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140227372A1 (en) | 2014-08-14 |
| RU2013157589A (ru) | 2015-06-27 |
| MX340453B (es) | 2016-07-08 |
| CA2836844A1 (en) | 2012-11-29 |
| EP2714926A1 (en) | 2014-04-09 |
| CN103562409A (zh) | 2014-02-05 |
| AU2012260785B2 (en) | 2016-02-11 |
| BR112013029787A2 (pt) | 2017-01-17 |
| WO2012160177A1 (en) | 2012-11-29 |
| HK1193637A1 (en) | 2014-09-26 |
| CN103562409B (zh) | 2016-04-27 |
| ES2550192T3 (es) | 2015-11-05 |
| AU2012260785A1 (en) | 2013-11-14 |
| EP2714926B1 (en) | 2015-07-22 |
| JP2014516531A (ja) | 2014-07-17 |
| SG194615A1 (en) | 2013-12-30 |
| PT2714926E (pt) | 2015-11-03 |
| MX2013013746A (es) | 2014-02-27 |
| KR20140024907A (ko) | 2014-03-03 |
| IL229319A0 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2714926T3 (pl) | Biomarkery raka płuca | |
| IL231426A (en) | Biological markers for lung cancer and their uses | |
| EP2841603A4 (en) | METHODS OF ASSESSING THE STATUS OF LUNG CANCER | |
| PL2931922T3 (pl) | Personalizowane biomarkery nowotworu | |
| GB201213567D0 (en) | Biomarkers | |
| EP2668295A4 (en) | METHODS OF DETECTING LUNG CANCER | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| GB2494580B (en) | Method for diagnosing lung cancer | |
| WO2012167112A9 (en) | Gastric cancer biomarkers | |
| GB201104556D0 (en) | Biomarkers | |
| GB201210565D0 (en) | Biomarkers | |
| GB201001444D0 (en) | Biomarkers | |
| IL235315A0 (en) | Biomarkers for the treatment of inhibitors of the type of apoptosis inhibitors | |
| GB2510539B (en) | Biomarkers of cancer | |
| IL231556A0 (en) | Biomarkers for infection of the respiratory system | |
| GB201004304D0 (en) | Biomarkers for prostate cancer | |
| IL232479A0 (en) | Combined treatment of ovarian cancer | |
| GB201113968D0 (en) | Prognostic methadology | |
| GB201001419D0 (en) | Biomarkers | |
| GB201107675D0 (en) | Prognostic biomarkers for lung diseases | |
| GB201119196D0 (en) | Biomarkers | |
| IL231330A0 (en) | Cancer diagnosis methods | |
| GB201121280D0 (en) | Biomarker | |
| GB201107838D0 (en) | Biomarker | |
| GB201118153D0 (en) | Therapies for cancers |